Camurus (OM:CAMX) Just Gave Investors Something To Think About

Health Canada approval puts Camurus in focus

Camurus (OM:CAMX) just received a Notice of Compliance from Health Canada for Oczyesa XR for maintenance treatment of acromegaly in adults who are already stabilized on somatostatin analogs.

The decision rests on seven clinical trials, including two Phase 3 ACROINNOVA studies that reported normalized IGF-1 levels, symptom relief, quality of life improvements and a safety profile comparable to existing somatostatin receptor ligands.

Health Canada's backing comes at a time when Camurus shares are showing firm upward momentum, with a 30-day share price return of 7.04% and a year-to-date share price gain of 5.64%, capped by a multi-year total shareholder return above 100%.

Scan beyond Camurus and see how other biopharma specialists with fresh regulatory catalysts line up in the 614 high quality undiscovered gems list.

Camurus appears to be a solid specialty pharma platform, supported by the expanding reach of Oczyesa and double-digit revenue and net income growth. After the recent share price move, the question is whether investors are still paying a fair price for that level of quality.

Most Popular Narrative: 6.6% Overvalued

On Simply Wall St, the leading valuation story pegs Camurus at a fair value of SEK606.54 against a last close of SEK646.5. This leaves the shares modestly above that narrative estimate and places more emphasis on how its drug delivery platform develops.

What I like about Camurus is the combination of an established pharmaceutical business, strong cash generation and a second potential growth engine that could scale through partnerships.

The existing medicines help fund the journey. FluidCrystal provides the optionality.

See why 1 investors see Camurus as 7% overvalued.

Result: Fair Value of SEK606.54 (OVERVALUED)

Still, Camurus faces real pressure if key FluidCrystal partnerships stall or if new long-acting competitors secure more attractive deals with larger pharmaceutical groups.

Find out about the key risks to this Camurus narrative.

Another View: SWS DCF Puts Camurus in a Different Light

The narrative fair value for Camurus sits at SEK606.54, slightly below the current SEK646.5 share price. Our DCF model provides a very different perspective. It estimates future cash flows at SEK1,310.61 per share, which presents the stock as heavily undervalued instead of mildly rich. Which lens do you consider more informative when the gap is this wide?

For readers who want to see how that figure is built step by step, the SWS DCF model is laid out in full detail, including key assumptions and sensitivities, in the valuation section of the company report. Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Camurus for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 191 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed signals on Camurus valuation and growth drivers can make the story feel complex, so move quickly and stress test the numbers yourself. To understand what investors view as the key upsides, review the 3 key rewards.

Looking for more investment ideas beyond Camurus?

If Camurus has your attention today, do not stop there. Broaden your watchlist now and give yourself more options before the next catalyst hits.

• Target long term compounding potential through quality businesses that trade below intrinsic estimates with the 191 high quality undervalued stocks.
• Prioritise capital preservation by scanning for companies that score well on resilience and financial risk using the 234 resilient stocks with low risk scores.
• Strengthen your core holdings with balance sheets that look robust and fundamentals that hold up under scrutiny through the list of solid balance sheet and fundamentals (204 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com